Check 35,000+ stocks against 26 valuation models and 37 quality factors

Tian'an Technology Group Ltd (TANAF) fair value: what the stock is really worth

As of Sep 28, 2026: fair value of Tian'an Technology Group Ltd $0.02, price $0.15, upside -86.7%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · US

Thin data Sep 27, 2026

Tian'an Technology Group Ltd

TANAF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0200 · Strongly overvalued (−86.7%)

!Quality 47/100

!Mixed Growth (revenue 3y +55.4 %/yr)

!Loss-making · -12.2% net margin (TTM)

✓Negative equity (buybacks among others) · generates free cash flow

!Trails peers (0/8)

!Narrow moat 10/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.0100 to bull $0.0200 Growth analysisrevenue history, year by year Quality 47/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Tian'an Technology Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

28‑month range $0.0956 – $17.40 · fair‑value band $0.0100 – $0.0200 · the $0.1500 price screens above the $0.0200 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Tian'an Technology Group in your weekly email

Every Wednesday you see whether Tian'an Technology Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tian'an Technology Group Ltd., through its subsidiaries, engages in the research, development, and production of graphene products for the health therapy industry in China.

Tian'an Technology Group Ltd., through its subsidiaries, engages in the research, development, and production of graphene products for the health therapy industry in China. The company offers graphene far infrared energy rooms, pure graphene heating music blankets, graphene pillows, pure graphene heating knee compartments, pure graphene heating knee pads, suspension moxibustion instrument, and pure graphene eye masks. It also develops an online technical support platform; provides after-sales and technical support services; and online medicine distribution platform to facilitate medication delivery for customers. The company was incorporated in 2021 and is based in Shanghai, China.

Stock analysis

Tian'an Technology Group Ltd (TANAF) currently trades at $0.1500, while our model-based Fair Value estimate is $0.0200, 86.7% below the price, so the stock looks overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of $0.0200 per share, and 0 of the 6 models we run sit above the $0.1500 price.

Bear case: the Multiples group reads lowest at $0.0100, and 6 of the 6 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0100 (bear) to $0.0200 (bull), the price of $0.1500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Tian'an Technology Group Ltd reported revenue of $735K in FY2025 versus $37.1K in FY2021, a compound +111.0%/yr. Reported net income was −$89.9K in FY2025.

Key figures

Market cap $22.8M · P/S ratio 31.0 · Net margin −12.2% · Return on assets (EBIT) −127% · Operating margin −41.2% · Revenue (TTM) $735K · Revenue growth (YoY) −84.0% · Free cash flow $126K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).

What moves the price

The share trades about 99% below its 52-week high and 57% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −87%, TANAF screens richer than that median.

Fair Value models

Bear $0.0100 Fair Value $0.0200 Bull $0.0200

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $0.0100 $0.0200 $0.0300 72

Growth DCF $0.0100 $0.0200 $0.0300 69

5Y Revenue Exit $0.0100 $0.0100 $0.0200 64

All 6 models by family

DCF Models

FCF DCF $0.0100 $0.0200 $0.0300 72

5Y Revenue Exit $0.0100 $0.0100 $0.0200 64

10Y Revenue Exit $0.0100 $0.0200 $0.0200 61

Multiples

EV/Revenue $0.0100 $0.0100 $0.0100 52

Growth DCF

Growth DCF $0.0100 $0.0200 $0.0300 69

Rev-Margin DCF $0.0100 $0.0100 $0.0300 58

Open the full fair value analysis →

Notify me when TANAF reaches fair value

Put TANAF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 53 · Market factors (momentum, volatility) 17

Profitability 44

Margins and returns on capital today

Quality Growth 0

Are margins and returns improving?

Cashflow 79

Earnings quality: real cash, not paper profit

Fin. Strength 57

Balance sheet, leverage, solvency risk

Investment 50

Disciplined investing over empire-building

Low Volatility 32

Calm price path (market factor)

Momentum 17

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 80

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 61/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

−58.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+55.4%

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−320.4% (2021) → −12.0% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+28.3%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +25.3% a year for the price.

TANAF screens overvalued: fair value 87% below the price. Compare with Abbott Laboratories, →

Compare Tian'an Technology Group Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 360 stocks

Beats the industry median on 0/8 measures

Overall it trails its industry peers.

Valuation

Quality Score 47 · Below median

Fair Value upside −86.7% · Bottom 25%

Profitability

Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Return on assets −6.8% · Below median

Net margin (TTM) −12.2% · Below median

Operating margin (TTM) −41.2% · Bottom 25%

Growth and dividend

Revenue growth −84.0% · Bottom 25%

Balance sheet

Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

P/S (TTM) 30.97× · Priciest 25%

P/FCF 180.5× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$101.29	$74.79	−26%
Medtronic plc MDT	$88.64	$65.61	−26%
Stryker Corporation SYK	$272.36	$299.60	+10%
Boston Scientific Corporation BSX	$43.92	$48.31	+10%
Edwards Lifesciences Corporation EW	$86.29	$81.94	−5%
Siemens Healthineers AG SHL	€37.79	€35.19	−7%
DexCom, Inc DXCM	$86.68	$95.35	+10%
GE HealthCare Technologies Inc GEHC	$66.63	$70.37	+6%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥153.86	¥169.25	+10%
Koninklijke Philips N.V PHIA	€21.87	€15.23	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tian'an Technology Group Ltd · Fair Value
$0.0200 −87%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/TANAF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Tian&#039;an Technology Group Ltd · Fair Value</span><br><b style="font-size:20px">$0.0200</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−87%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Tian'an Technology Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/TANAF

Frequently asked questions

Is Tian'an Technology Group Ltd (TANAF) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of $0.0200 versus a price of $0.1500, about −87% upside (overvalued).

What is the fair value of TANAF?

Our model-based fair value for Tian'an Technology Group Ltd is $0.0200 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.1500.

What is the quality score of TANAF?

Tian'an Technology Group Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Tian'an Technology Group Ltd (TANAF)?

Our model-based price target is the fair value of $0.0200 (as of Sep 27, 2026) from 6 valuation models. Cautious scenario $0.0100, optimistic scenario $0.0200. It is a calculation from audited fundamentals, not an analyst target.

What is the Tian'an Technology Group Ltd stock forecast for 2026?

Our models put fair value at $0.0200, about −87% upside versus a price of $0.1500 (overvalued). Cautious scenario $0.0100, optimistic scenario $0.0200. The calculation is refreshed regularly with new filings.

What is the revenue of Tian'an Technology Group Ltd (TANAF)?

Tian'an Technology Group Ltd reported trailing-twelve-month revenue of about $735K (latest available figure, as of Sep 27, 2026).

What growth is priced into Tian'an Technology Group Ltd (TANAF)?

For today's price to be fair in a discounted-cash-flow model, Tian'an Technology Group Ltd would have to grow free cash flow by +28.3 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +111.0 % per year. As of Sep 27, 2026.

What discount rate (WACC) does the fair value of TANAF use?

Our models discount Tian'an Technology Group Ltd at 9.7 %: a base by market capitalisation (nano), damped by beta 0.98, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tian'an Technology Group Ltd that is +28.3 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.

How much growth has Tian'an Technology Group Ltd (TANAF) delivered so far?

Over the past 4 years revenue at Tian'an Technology Group Ltd grew +111.0 % a year. The price currently implies +28.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Tian'an Technology Group Ltd (TANAF) growing?

The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Tian'an Technology Group Ltd (+28.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Tian'an Technology Group Ltd (TANAF)?

The free-cash-flow yield on the price is 1.85 %: that much free cash flow Tian'an Technology Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Tian'an Technology Group Ltd (TANAF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tian'an Technology Group Ltd it is $0.0200 per share (as of Sep 27, 2026), against a price of $0.1500. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).

Is Tian'an Technology Group Ltd stock overvalued or undervalued in 2026?

As of Sep 27, 2026, TANAF trades above its calculated fair value: price $0.1500, fair value $0.0200, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of TANAF?

No. The price is what the market pays today ($0.1500); the fair value is what the company's own numbers justify ($0.0200). For Tian'an Technology Group Ltd the two are $0.1300 per share apart. That gap is exactly why we show both numbers side by side.

How much is Tian'an Technology Group Ltd worth?

The market values Tian'an Technology Group Ltd at about $22.8M (market capitalisation, as of Sep 27, 2026). Per share that is $0.1500; our models calculate a fair value of $0.0200 per share.

What do the bullish and bearish scenarios say about TANAF?

Our models span a range for Tian'an Technology Group Ltd: cautious scenario $0.0100, base $0.0200, optimistic $0.0200 per share (as of Sep 27, 2026, price $0.1500). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Tian'an Technology Group Ltd (TANAF)?

Balance-sheet figures for Tian'an Technology Group Ltd (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 47/100, which measures business quality independently of the share price.

How far is TANAF from its 52-week high?

Tian'an Technology Group Ltd trades at $0.1500, about 99% below its 52-week high of $15.79 and 57% above the low of $0.0956 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0200 is for.

Which stocks are comparable to Tian'an Technology Group Ltd?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Tian'an Technology Group Ltd stock attractive at the current price?

The data as of Sep 27, 2026: price $0.1500, calculated fair value $0.0200 (−87%), Quality Score 47/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of TANAF calculated?

We run Tian'an Technology Group Ltd through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0200, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.9 % above its aggregate fair value. Tian'an Technology Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Tian'an Technology Group Ltd (TANAF)?

The closing price on Sep 28, 2026 was $0.1500. Our model-based fair value is $0.0200, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Tian'an Technology Group Ltd right now?

The price sits above even our optimistic bull case ($0.0200). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.0100 to $0.0200) leaves room in how you read the outcome.

Key figures of Tian'an Technology Group Ltd

How large is the market capitalisation of Tian'an Technology Group Ltd (TANAF)?

The market capitalisation of Tian'an Technology Group Ltd is $22.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Tian'an Technology Group Ltd (TANAF)?

The price-to-sales ratio of Tian'an Technology Group Ltd is 31.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the net margin of Tian'an Technology Group Ltd (TANAF)?

The net margin of Tian'an Technology Group Ltd is −12.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the EBIT return on assets of Tian'an Technology Group Ltd (TANAF)?

On an EBIT basis the return on assets of Tian'an Technology Group Ltd is −127% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Tian'an Technology Group Ltd (TANAF)?

The operating margin of Tian'an Technology Group Ltd is −41.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Tian'an Technology Group Ltd (TANAF)?

Revenue at Tian'an Technology Group Ltd is growing −84.0% versus a year earlier (3y avg +55.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

Free · no account needed

Watch Tian'an Technology Group Ltd in the live analysis

One click puts Tian'an Technology Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.